Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
<p>Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.</p>
محفوظ في:
| المؤلف الرئيسي: | Seyed Reza Mousavi (13223324) (author) |
|---|---|
| مؤلفون آخرون: | Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author) |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
حسب: Seyed Reza Mousavi (13223324)
منشور في: (2025) -
The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
حسب: Seyed Reza Mousavi (13223324)
منشور في: (2025) -
Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
حسب: Seyed Reza Mousavi (13223324)
منشور في: (2025) -
Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
حسب: Seyed Reza Mousavi (13223324)
منشور في: (2025) -
Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
حسب: Anna Starshinova (22571846)
منشور في: (2025)